Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24410357 | 0.81 | MCL1 (0.38) | MCL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL573401 | 0.79 | — | — | |
| SCHEMBL1011084 | 0.77 | — | — | |
| SCHEMBL1013569 | 0.76 | MCL1 (0.38) | MCL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3391018 | 0.76 | MCL1 (0.38) | MCL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1012319 | 0.75 | — | — | |
| SCHEMBL15156953 | 0.75 | — | — | |
| Trifluoroacetic Acid SCHEMBL2214877 | 0.73 | MCL1 (0.39) | MCL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1583542 | 0.71 | MCL1 (0.40) | MCL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23982819 | 0.71 | MCL1 (0.38) | MCL1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4406387-A1 | AN ORGANIC ELECTRONIC DEVICE COMPRISING A SUBSTRATE, AN ANODE LAYER, A CATHODE LAYER, AT LEAST ONE FIRST EMISSION LAYER, AND A HOLE INJECTION LAYER, WHEREIN THE HOLE INJECTION LAYER COMPRISES A METAL COMPLEX OF FORMULA (I) AND A COMPOUND OF FORMULA (II), WHEREIN THE HOLE INJECTION LAYER IS ARRANGED BETWEEN THE ANODE LAYER AND THE AT LEAST ONE FIRST EMISSION LAYER | Novaled GmbH (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023041767-A1 | AN ORGANIC ELECTRONIC DEVICE COMPRISING A SUBSTRATE, AN ANODE LAYER, A CATHODE LAYER, AT LEAST ONE FIRST EMISSION LAYER, AND A HOLE INJECTION LAYER, WHEREIN THE HOLE INJECTION LAYER COMPRISES A METAL COMPLEX OF FORMULA (I) AND A COMPOUND OF FORMULA (II), WHEREIN THE HOLE INJECTION LAYER IS ARRANGED BETWEEN THE ANODE LAYER AND THE AT LEAST ONE FIRST EMISSION LAYER | NOVALED GMBH (DE) | 2023-03-23 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| EP-1943243-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053346-A1 | PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053394-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
| EP-0375670-B1 | Process for preparing 3-polyfluoroalkylisoxazolylamines | SHIONOGI & CO (JP) | 1997-08-06 | — | — | EP | disclosed |
| EP-0220947-B1 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0375670-A2 | Process for preparing 3-polyfluoroalkylisoxazolylamines | SHIONOGI & CO., LTD. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4910326-A | β-ketonitrils | SHIONOGI & CO., LTD. (JP) | 1990-03-20 | — | — | US | disclosed |
| EP-0304966-A2 | Beta-ketonitriles | SHIONOGI & CO., LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4797492-A | INTERMEDIATES FOR BACTERICIDES; HERBICIDES OR FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 1989-01-10 | — | — | US | disclosed |
| EP-0220947-A2 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | MCL1 291/4885LIPA 3215/4885CYP1A2 4571/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | MCL1 84/4885LIPA 4182/4885CYP1A2 3220/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MCL1 291/4885LIPA 3215/4885CYP1A2 4571/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | MCL1 84/4885LIPA 4182/4885CYP1A2 3220/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | MCL1 84/4885LIPA 4182/4885CYP1A2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.